Anjali Hari, MD, Speaks to Survival/Safety Outcomes With HIPEC in Frail and Non-Frail Ovarian Cancer

Anjali Hari, MD, discusses survival and safety outcomes with hyperthermic intraperitoneal chemotherapy in frail and non-frail patients with ovarian cancer.

In an interview with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, Anjali Y. Hari, MD, an obstetrician-gynecologist at the University of California (UC), Irvine, School of Medicine, spoke about efficacy and safety findings with hyperthermic intraperitoneal chemotherapy (HIPEC) in frail and non-frail patients with ovarian cancer.

In particular, Hari stated that a nonsignificant difference in progression-free survival (PFS) was observed between the frail and non-frail groups. Additionally, no notable difference in safety was observed.

Transcript:

The survival outcomes were very similar. PFS was about 12 months for frail patients vs 14 months for non-frail patients, but this was not significant. Then postoperatively, hospital stays, ICU stays, sepsis, and anastomotic leak rates were all very similar between frail and non-frail patients. Again, there were no big safety issues, which we found was a good thing. Our patients did very similarly postoperatively in terms of their hospital stays, and complications.

Reference

Hari A, Furey K, Jou J, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) outcomes across 3 academic institutions among frail and non-frail patients. Presented at: Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer. March 18-21, 2022. Phoenix, AZ.